Doctors no longer have to use Framingham equation to assessheart disease risk, NICE saysBMJ 2010; 340 doi: http://dx.doi.org/10.1136/bmj.c1774 (Published 29 March 2010) Cite this as: BMJ 2010;340:c1774
- Susan Mayor
Healthcare professionals in the United Kingdom should use the cardiovascular risk assessment tool they consider most appropriate when assessing whether to prescribe lipid modifying therapy for the primary prevention of cardiovascular disease, an updated guideline from the National Institute for Health and Clinical Excellence (NICE) said this week.
It downgrades the previous recommendation that the US derived Framingham risk equation should be used as the risk scoring tool of choice.
The NICE guideline recommends that healthcare professionals use a systematic strategy for identifying people likely to be at high risk for cardiovascular disease who would benefit from lipid modifying therapy.
The guideline recommends use of a risk equation to assess …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial